文献速递产科母胎医学

母胎医学会特别声明:产前糖皮质激素最佳给药时机的质量指标

Society for Maternal-Fetal Medicine Special Statement: Quality metrics for optimal timing of antenatal corticosteroid administration.
PubMed 文献 · Am J Obstet Gynecol · 2022-02-18

该声明提出产前糖皮质激素最佳时机质量指标的规范,并建议一个平衡指标追踪接受治疗但最终足月分娩的患者比例。声明指出,仅在分娩前7天内给药才最有效,而现有指标未评估时机,新指标可能促使更保守的给药时机,从而改善早产儿结局。

要点

  • 产前糖皮质激素在早产前7天内给药效果最佳,但仅20%至40%的早期早产儿在此窗口内接受治疗。
  • 2020年之前,联合委员会(The Joint Commission)的围产期护理质量指标仅评估任何时间的给药率,未评估时机。
  • 建议新指标评估最佳时机给药率,并建议平衡指标追踪接受治疗但最终足月分娩的比例。

核心结论

  • 建议使用新的产前糖皮质激素最佳时机质量指标及平衡指标,可能促使更保守的给药时机,从而改善早产儿结局。

研究设计与样本

  • 母胎医学会(Society for Maternal-Fetal Medicine)特别声明,提出质量指标规范并讨论其用途、优势、局限和障碍。

主要发现

  • 仅20%至40%的早期早产儿在出生前7天内接受产前糖皮质激素。
  • 联合委员会认证医院的产前糖皮质激素给药率超过97%后,该指标于2020年被废止。
  • 2016年多利益相关方合作研讨会建议开发新质量指标评估最佳时机给药率。

关键数值与推荐

  • 产前糖皮质激素在早产前7天内给药时效果最佳。
  • 建议的质量指标评估早期早产中最佳时机产前糖皮质激素给药率。
  • 建议的平衡指标追踪接受产前糖皮质激素治疗但最终足月分娩的患者百分比。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Preterm birth is a leading cause of perinatal morbidity and mortality. Antenatal corticosteroid administration before preterm birth reduces the risks of perinatal death, respiratory morbidity, necrotizing enterocolitis, and intraventricular hemorrhage and reduces the costs of perinatal care. Antenatal corticosteroids are optimally effective when administered within 7 days before preterm birth. However, only 20% to 40% of early preterm infants receive antenatal corticosteroids within 7 days before birth, in part because it is difficult to predict the precise timing of preterm birth. Until 2020, The Joint Commission had a Perinatal Care quality metric measuring the rate of antenatal corticosteroid administration at any time before early preterm birth. This metric incentivized providers to use antenatal corticosteroids liberally. The Joint Commission retired the metric in 2020 after the rate reached more than 97% in The Joint Commission-accredited hospitals. However, the metric did not evaluate whether the timing of antenatal corticosteroid administration was optimal, that is, within 7 days of birth. A 2016 multistakeholder Cooperative Workshop recommended the development of a new quality metric to assess the rate of optimally timed antenatal corticosteroids among early preterm births. In this statement, we outline proposed specifications for such a metric and discuss potential uses, advantages, limitations, and barriers. Furthermore, we propose a balancing metric that tracks the percentage of patients treated with antenatal corticosteroids who ultimately give birth at term. We suggest that the use of these new metrics may incentivize more conservative antenatal corticosteroid timing, which could, in turn, lead to meaningfully improved outcomes for preterm neonates.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Hamm RF, Combs CA, Aghajanian P, et al. Society for Maternal-Fetal Medicine Special Statement: Quality metrics for optimal timing of antenatal corticosteroid administration. Am J Obstet Gynecol. 2022. PMID: 35189094. doi:10.1016/j.ajog.2022.02.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。